Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 42.34B | 41.95B | 40.11B | 43.65B | 43.08B | 34.61B |
Gross Profit | 23.67B | 23.24B | 22.13B | 24.51B | 24.54B | 19.61B |
EBITDA | 11.20B | 10.83B | 10.61B | 12.38B | 12.74B | 8.79B |
Net Income | 13.50B | 13.40B | 5.72B | 6.93B | 7.07B | 4.50B |
Balance Sheet | ||||||
Total Assets | 81.45B | 81.41B | 73.21B | 74.44B | 75.20B | 72.55B |
Cash, Cash Equivalents and Short-Term Investments | 6.84B | 7.97B | 7.28B | 10.17B | 10.25B | 7.15B |
Total Debt | 13.24B | 15.02B | 15.87B | 17.72B | 19.01B | 19.65B |
Total Liabilities | 32.38B | 33.51B | 34.39B | 37.53B | 39.17B | 39.55B |
Stockholders Equity | 48.81B | 47.66B | 38.60B | 36.69B | 35.80B | 32.78B |
Cash Flow | ||||||
Free Cash Flow | 6.66B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B |
Operating Cash Flow | 8.95B | 8.56B | 7.26B | 9.58B | 10.53B | 7.90B |
Investing Cash Flow | -2.38B | -2.34B | -3.13B | -1.74B | -2.01B | -2.21B |
Financing Cash Flow | -6.28B | -5.40B | -7.09B | -7.64B | -5.49B | -2.78B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $150.40B | 53.11 | 14.26% | 0.85% | 10.76% | -15.22% | |
80 Outperform | $233.80B | 17.43 | 30.66% | 1.76% | 5.00% | 139.98% | |
78 Outperform | $33.85B | 64.81 | 23.72% | ― | 9.11% | -17.87% | |
77 Outperform | $110.21B | 23.80 | 9.49% | 3.30% | 3.62% | 31.18% | |
72 Outperform | $157.61B | 78.06 | 9.65% | ― | 19.35% | 14.31% | |
64 Neutral | $45.88B | 52.25 | 16.73% | ― | -9.84% | -35.77% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% |
On April 25, 2025, Abbott Laboratories announced that Hubert L. Allen, the Executive Vice President, General Counsel, and Secretary, plans to retire after a transition period. This leadership change could impact the company’s operations and strategic direction, potentially influencing its market positioning and stakeholder relationships.